Dental Pain Clinical Trial
Official title:
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Analgesic Efficacy Trial of Oral ARRY-371797 in Subjects Undergoing Third Molar Extraction
Verified date | February 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.
Status | Completed |
Enrollment | 250 |
Est. completion date | June 20, 2008 |
Est. primary completion date | June 20, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Key Inclusion Criteria: - Scheduled for outpatient oral surgical procedure to remove 3 or more third molars, at least 1 of which is mandibular and fully or partially impacted by bone. - Females of childbearing potential must be willing to use an acceptable method of contraception within 14 days prior to first dose of study drug until the completion of the follow-up procedures. - Body weight >50 kg (110 lbs). - Good health determined by medical history, physical examination, vital signs and clinical laboratory results of non-clinical significance. - Additional criteria exist. Key Exclusion Criteria: - Evidence or history of clinically significant dermatologic, hematological, renal, endocrine (e.g. poorly controlled diabetes), pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, ophthalmologic, or allergic disease (including clinically significant drug allergies that could impact the conduct of this study, but excluding untreated, asymptomatic, seasonal allergies at time of study drug dosing). - Positive urine drug screen within 28 days prior to first dose of study drug. - Use of prohibited prescription drugs, or grapefruit juice within 7 days of first dose of study drug; prohibited medications are defined as nonsteroidal and steroidal antiinflammatory drugs, analgesics including opioids (except low dose aspirin for myocardial infarction prophylaxis), P450 CYP3A substrates or inhibitors (strong or moderate). - Additional criteria exist. |
Country | Name | City | State |
---|---|---|---|
United States | PPD Phase I Clinic | Austin | Texas |
United States | Lifetree Clinical Research | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR). | 6 hours post-dose | ||
Primary | Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs. | Duration of study | ||
Secondary | Assess the efficacy of the study drug (versus placebo and celecoxib) in terms of pain relief measurements [including TOTPAR, total pain intensity (TPI) and time to rescue medication]. | Duration of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00942448 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT00943098 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT00954356 -
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
|
Phase 2 | |
Completed |
NCT00985439 -
Study of Diclofenac Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT02966067 -
A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery
|
N/A | |
Completed |
NCT01960114 -
Study of Long-Acting Acetaminophen in Postoperative Dental Pain
|
Phase 2 | |
Completed |
NCT01229228 -
Study of Naproxen Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT01177423 -
Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block
|
N/A | |
Completed |
NCT03328208 -
Nonpharmacologic Reduction of Periprocedural Distress and Drug Use
|
N/A | |
Completed |
NCT05236101 -
Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety
|
N/A | |
Completed |
NCT00542035 -
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
|
Phase 2 | |
Completed |
NCT04231955 -
Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth
|
N/A | |
Completed |
NCT02096926 -
Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery
|
Phase 4 | |
Completed |
NCT05369936 -
Pain Perception: on Relationships Between Dental Anxiety and Olfaction
|
N/A | |
Recruiting |
NCT05351099 -
Dental Block for Pain Relief in ED Dental Pain Patients
|
||
Not yet recruiting |
NCT06269406 -
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
|
N/A | |
Recruiting |
NCT05443009 -
Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction
|
Phase 4 | |
Terminated |
NCT02161354 -
Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars
|
Phase 2 | |
Completed |
NCT04949126 -
Self Medication in Odontology (AUDE)
|
||
Completed |
NCT03652818 -
Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
|
Phase 2 |